Search Results for: CANCER IMMUNOTHERAPY Building on Initial
Articles
CANCER IMMUNOTHERAPY - Building on Initial Successes to Improve Clinical Outcomes November 20, 2017
Allan B. Haberman, PhD, provides an updated discussion of approved and clinical-stage agents in immuno-oncology, including recently approved agents. He also addresses how researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients.
CERo Therapeutics Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia April 9, 2025
CERo Therapeutics Holdings, Inc. recently announced its first clinical trial site for the its Phase 1 clinical trial of CER-1236. ...BioNTech & DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate in Prostate Cancer June 24, 2024
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT324/DB-1311 for the treatment of...THERAPEUTIC FOCUS - Addressing the Unmet Need for Improved Treatments of Female Cancers January 16, 2023
Martin Lehr, MA, explains how his company is advancing a pipeline of innovative products designed to address treatment resistance in breast, ovarian, and endometrial cancer, which, if approved, could provide patients with a much-needed new treatment options.
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept January 30, 2020
Avacta Group plc recently announced it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in...Recipharm and Fusix Biotech advance novel oncolytic virus platform June 8, 2026
Recipharm, a leading global contract development and manufacturing organization (CDMO), today announced a strategic collaboration with Fusix Biotech to support...SPECIAL FEATURE- Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure June 4, 2025
Contributor Cindy H. Dubin speaks with many CDMO professionals to get their insights and perspectives on the current state of the industry.
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA From Pretargeted RIT Platform April 27, 2025
Y-mAbs Therapeutics, Inc. recently announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at...CERo Therapeutics Holdings Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing March 27, 2025
CERo Therapeutics Holdings, Inc. recently announced that the company has received positive review from the US FDA on an amendment...Lisata Therapeutics & WARPNINE Announce Encouraging Preliminary Results From Phase 1b/2a iLSTA Trial January 23, 2025
Lisata Therapeutics, Inc. and WARPNINE Incorporated recently announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (ACTRN12623000223639) evaluating certepetide...BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate January 31, 2024
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
BioNTech & Crescendo Biologics Announce Global Collaboration to Develop Multi-Specific Precision Immunotherapies January 10, 2022
BioNTech SE and Crescendo Biologics Ltd. recently announced they have entered a multi-target discovery collaboration to develop novel immunotherapies for the...ARTIFICIAL INTELLIGENCE - Attempting to Speed Up Vaccine Development to Combat the Next Pandemic October 4, 2021
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology February 14, 2020
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
LDC & SOTIO Enter License & Collaboration Agreement April 17, 2017
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI), and SOTIO a.s. have signed a collaboration and license...DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
CiMaas & PharmaCell BV Enter Collaborative Agreement July 14, 2015
CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies...Juno Therapeutics Raises IPO Target to $191 Million December 16, 2014
Seattle cancer-immunotherapy company Juno Therapeutics recently announced it has upped the target for its pending initial public offering of stock...12/6/2011 December 4, 2011
Nanion's SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp Users Nanion's ion channel screening platform, the SyncroPatch 96, has been...
